1002 completed, 317 terminated, 306 unknown, 247 recruiting. 2186 Phase 2, 378 Phase 1, 76 Phase 3.
Follow Breast Cancer: new trials by email Literature Review of Breast Cancer trials Research Report on Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi-4SCAR-T Therapy Targeting Breast Cancer 4SCAR T cells - Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-06-01 | 2026-08-26 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction) Empagliflozin - Breast Cancer, Supportive Care in Cancer | Phase 2 | Not yet recruiting | Virginia Commonwealth University | 10 | 2026-12-01 | 2026-10-20 |
| Evaluation of the Effect of Amantadine in the Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients Amantadine (oral) - Breast Cancer, Peripheral Neuropathy Due to Chemotherapy | Phase 2 | Not yet recruiting | Al-Azhar University | 80 | 2026-12-01 | 2026-10-22 |
| Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment Thymalfasin - Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 572 | 2026-11-08 | 2026-10-20 |
| Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) Trilaciclib, Eribulin - Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 29 | 2026-11-04 | 2025-12-01 |
| DiEtary Mimicry by Glucocorticoid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Efficacy and Response (DEMETER Trial) Dexamethasone (Oral) - Breast Cancer | Phase 2 | Not yet recruiting | The Netherlands Cancer Institute | 80 | 2026-11-01 | 2026-08-25 |
| Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast Tumors Mini rTG OMEGA-3 Fish Oil - Breast Cancer | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 35 | 2026-11-01 | 2026-10-20 |
| Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer Trastuzumab deruxtecan, Lovastatin - Breast Cancer, Advanced Breast Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 60 | 2026-10-31 | 2026-09-22 |
| A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes Inavolisib, Fulvestrant, Palbociclib - Breast Cancer, Diabetes Type II | Phase 2 | Recruiting | Hoffmann-La Roche | 40 | 2026-10-30 | 2026-10-20 |
| Single FrAction Interstitial BreaSt BracHytherApy Partial Breast Irradiation - Breast Cancer | Phase 2 | Recruiting | Virginia Commonwealth University | 134 | 2026-10-19 | 2026-10-23 |
| Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches Liquid biopsy next generation sequencing - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Not yet recruiting | University College Cork | 50 | 2026-10-10 | 2026-10-26 |
| A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd Trastuzumab Deruxtecan (T-DXd), Pyrotinib - Breast Cancer | Phase 2 | Not yet recruiting | Fujian Medical University | 28 | 2026-10-10 | 2026-09-23 |
| Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) Taletrectinib - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Suspended | Megan Kruse, MD | 61 | 2026-10-01 | 2026-06-05 |
| ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer Aromatase inhibitor (± ovarian suppression) plus Ribociclib, 4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy - Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 388 | 2026-10-01 | 2026-02-20 |
| De-Escalation of Axillary Management in Advanced Nodal Disease Axillary Surgery - Breast Cancer | Phase 2 | Not yet recruiting | University of Kansas Medical Center | 120 | 2026-10-01 | 2026-10-16 |
| QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy Iparomlimab and Tuvonralimab (QL1706), Aromatase Inhibitor (AI), CDK4/6 inhibitor - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 40 | 2026-10-01 | 2026-08-26 |
| Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer Fulvestaciclib, Trastuzumab, Pertuzumab - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 240 | 2026-10-01 | 2026-07-21 |
| Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy Hyperbaric oxygen treatment, Standard Care (in control arm) - Breast Cancer, CIPN - Chemotherapy-Induced Peripheral Neuropathy | Phase 2 / Phase 3 | Recruiting | Guangdong Provincial People's Hospital | 160 | 2026-09-29 | 2026-09-30 |
| Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer Neoadjuvant Chemotherapy, Radiation Therapy, MRI - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 84 | 2026-09-15 | 2026-06-24 |
Showing 20 of 2186. Sign in to see all of them.
Breast Neoplasms (2186) · Neoplasm Metastasis (111) · Triple Negative Breast Neoplasms (111) · Ovarian Neoplasms (92) · Breast Neoplasms, Male (82) · Neoplasms (76) · Lung Neoplasms (73) · Carcinoma, Non-Small-Cell Lung (62) · Colorectal Neoplasms (58) · Prostatic Neoplasms (56) · Pancreatic Neoplasms (50) · Melanoma (41) · Brain Neoplasms (40) · Stomach Neoplasms (38) · Carcinoma, Intraductal, Noninfiltrating (35)
Skin Diseases (2186) · Skin and Connective Tissue Diseases (2186) · Neoplasms by Site (2183) · Breast Diseases (2180) · Neoplasms (2110) · Pathological Conditions, Signs and Symptoms (231) · Neoplasms by Histologic Type (184) · Pathologic Processes (182) · Urogenital Diseases (155) · Urogenital Neoplasms (149) · Neoplasms, Glandular and Epithelial (143) · Genital Diseases (141) · Female Urogenital Diseases (131) · Female Urogenital Diseases and Pregnancy Complications (131) · Carcinoma (130)
Trastuzumab (248) · Cyclophosphamide (225) · Docetaxel (199) · Paclitaxel (196) · Capecitabine (133) · Carboplatin (129) · Letrozole (127) · Doxorubicin (126) · Fulvestrant (92) · Bevacizumab (82) · Anastrozole (74) · Epirubicin (73) · Tamoxifen (69) · Gemcitabine (65) · pertuzumab (62)
Fudan University (56) · Memorial Sloan Kettering Cancer Center (53) · Hoffmann-La Roche (48) · Dana-Farber Cancer Institute (47) · M.D. Anderson Cancer Center (43) · National Cancer Institute (NCI) (38) · Alliance for Clinical Trials in Oncology (30) · Eli Lilly and Company (27) · AstraZeneca (21) · SCRI Development Innovations, LLC (20) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (20) · UNC Lineberger Comprehensive Cancer Center (20) · Novartis Pharmaceuticals (18) · Sun Yat-sen University (18) · H. Lee Moffitt Cancer Center and Research Institute (17)
United States (1113) · China (292) · Spain (165) · France (146) · Canada (129) · United Kingdom (120) · Italy (113) · Germany (97) · Belgium (91) · South Korea (79) · Australia (62) · Netherlands (49) · Brazil (43) · Taiwan (42) · Singapore (40)
Mothaffar Rimawi, MD (12) · Denise A. Yardley, MD (10) · Edith A. Perez, MD (10) · Norman Wolmark, MD (9) · Dimitris Mavrudis, MD (8) · Hope S. Rugo, MD (8) · Sara Tolaney, MD, MPH (8) · William J. Gradishar, MD (8)
PMID 34037241, PMID 38979716, PMID 33736679, PMID 12473512, PMID 21730275, PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 23044556, PMID 24327334, PMID 28057664, PMID 29530935, PMID 30627694, PMID 31615937, PMID 31838010, PMID 32001832, PMID 32053137, PMID 32450725, PMID 32880602, PMID 33084020, PMID 33138866, PMID 35537408, PMID 38745646, PMID 40443562, PMID 42334791, PMID 10080589, PMID 10210538, PMID 10227040, PMID 10561296, PMID 10574414, PMID 10628376, PMID 10766175, PMID 10964265, PMID 11160563, PMID 11206194, PMID 11230490, PMID 11352950, PMID 11516635, PMID 11530286, PMID 11745247, PMID 11815400, PMID 11882333, PMID 11893482, PMID 11999415, PMID 12006121, PMID 12138395, PMID 12196717, PMID 12533263, PMID 12610186
2023 (20), 2008 (16), 2014 (15), 2016 (14), 2009 (10), 2018 (10), 2019 (10), P30CA006973 (10), 2025 (9), P30CA033572 (9), P30CA043703 (9), U10CA032102 (9), 2017 (8), 2015 (7), P30CA072720 (7)